Showing 5971-5980 of 9846 results for "".
- AADA Statement on Legislative Interference in Health Care for Transgender Patientshttps://practicaldermatology.com/news/aada-statement-on-legislative-interference-in-health-care-for-transgender-patients/2460817/The American Academy of Dermatology Association strongly opposes recent efforts by state legislatures to restrict physicians’ ability to provide care to transgender youths. Legislation such as the bill enacted this spring in Arkansas as well as those proposed in several other states are a d
- Cosentyx Now Approved for Psoriasis in Children as Young as Sixhttps://practicaldermatology.com/news/cosentyx-now-approved-for-psoriasis-in-children-as-young-as-six/2460815/Cosentyx® (secukinumab) from Novartis is now FDA approved for the treatment of moderate to severe plaque psoriasis in pediatric patients six years and older who are candidates for systemic therapy or phototherapy. This is the first approval for Cosentyx in a pediatric population in the U
- Bliss Becomes First Mass & Drug Skincare Brand to Receive B Corp Certificationhttps://practicaldermatology.com/news/bliss-becomes-first-mass-drug-skincare-brand-to-receive-b-corp-certification/2460814/Bliss is the first-ever skincare brand sold at mass and drug to achieve B Corp Certification. This certification confirms that Bliss meets the highest standards of verified social and environmental performance, public transparency, and legal accountability to balance pr
- AAD Survey: Americans Are Confused About Sunscreen Usehttps://practicaldermatology.com/news/aad-survey-americans-are-confused-about-sunscreen-use/2460812/Your patients likely need a refresher course on sunscreen application and SPF. This is the main takeaway message of a recent survey of 1,000 U.S. adults by the American Academy of Dermatology. While 80 percent of Americans know they should apply sunscreen every two hours when outdoors,
- BioFactura Starts Phase I Study of BFI-751, a Stelara Biosimilarhttps://practicaldermatology.com/news/biofactura-starts-phase-i-study-of-bfi-751-a-stelara-biosimilar/2460811/BioFactura is set to begin a pivotal pharmacokinetics Phase 1 clinical trial for its Ustekinumab biosimilar BFI-751. The first-in-human Phase I study will assess the effects on healthy human volunteers compared to the biologic medicine, Stelara. This is the first time BFI-751 has been a
- Dermatological Agents, NSAIDs Are Leading Prescription Cost Drivers in New 28-State WCRI Drug Trends Studyhttps://practicaldermatology.com/news/dermatological-agents-nsaids-are-leading-prescription-cost-drivers-in-new-28-state-wcri-drug-trends-study/2460809/In most states, dermatological agents accounted for about 20 percent of total prescription payments in the first quarter of 2020 (2020Q1), according to a
- Medivir’s Remetinostat Shows Promise for SCChttps://practicaldermatology.com/news/medivirs-remetinostat-shows-promise-for-scc/2460807/Topical remetinostat gel performed well in a small investigator-initiated phase II clinical study of patients with squamous cell carcinoma. Four patients with five cutaneous SCCs were included in this case series and treated with remetinostat gel 1%. All five tumors, including
- Abbvie’s JAK1 Inhibitor Measures Up in Two Phase 3 Studies of ADhttps://practicaldermatology.com/news/abbvies-jak1-inhibitor-measures-up-in-two-phase-3-studies-of-ad/2460806/Upadacitinib yields rapid and significant improvements in patients with moderate to severe atopic dermatitis, according to results from two phase 3 clinical trials published online in The Lancet. Patients who received upadacitinib showed reductions in all clinical disease meas
- Lotrimin Taps WWE Superstar and Soles4Souls to Kick Foot Shame to the Curb and Encourage People to #GoWithConfidencehttps://practicaldermatology.com/news/lotrimin-taps-wwe-superstar-and-soles4souls-to-kick-foot-shame-to-the-curb-and-encourage-people-to-gowithconfidence/2460805/Lotrimin is teaming up with WWE Superstar The Miz to educate people on healthy feet habits and help people from all walks of life to #GoWithConfidence through a partnership with Soles4Souls – a nonprofit organization that turns unwanted shoes and clothing into opportunities for people in ne
- Curcumin Nanoparticles May Be Viable Adjuvant for Sunscreenhttps://practicaldermatology.com/news/curcumin-nanoparticles-may-be-viable-adjuvant-for-sunscreen/2460803/Curcumin may be a viable photoprotective adjuvant when delivered through nanoparticles, according to research published by a collaborative team from the George Washington University (GW) School of Medicine and Health Sciences (SMHS) Department of Dermatology and Albert Einstein College of Medicin